Tiziana Life Sciences Ltd
HealthcareNASDAQ:TLSA · NASDAQ Global Market
-$0.03 today
Vol 0.42M · Avg 0.20M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$34.9M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.63, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $234.0K | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$234.0K | $0 | $0 | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $10.3M +96.6% | $5.2M -49.0% | $10.3M -35.6% | $15.9M -10.6% | $17.8M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $10.8M | $0 | $0 | $0 -100.0% | $1.2M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $21.1M +33.3% | $15.8M -30.5% | $22.7M +26.8% | $17.9M -51.5% | $36.9M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $234.0K +88.7% | $124.0K +2.2% | $121.3K +93.6% | $62.7K -67.0% | $190.2K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$21.1M -26.7% | -$16.6M +23.3% | -$21.7M -14.9% | -$18.9M +46.9% | -$35.5M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$21.3M -34.8% | -$15.8M +30.5% | -$22.7M -26.8% | -$17.9M +51.5% | -$36.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $19.0K -97.7% | $814.0K -44.2% | $1.5M | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $18.0K +200.0% | $6.0K -52.5% | $12.6K +46.9% | $8.6K -96.4% | $237.4K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $2.9M +399.7% | -$952.0K -201.5% | $937.9K +194.1% | -$996.8K -203.1% | $967.2K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$18.4M -10.1% | -$16.7M +23.2% | -$21.8M -15.2% | -$18.9M +47.4% | -$36.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 +100.0% | -$4.9M -960.4% | $567.5K | $0 +100.0% | -$4.4M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$18.4M -55.4% | -$11.9M +46.9% | -$22.4M -18.2% | -$18.9M +40.1% | -$31.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 -45.5% | -$0 +47.6% | -$0 -16.7% | -$0 +43.8% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 -45.5% | -$0 +47.6% | -$0 -16.7% | -$0 +43.8% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $59.1M +10.9% | $53.3M +5.1% | $50.8M +0.0% | $50.8M +3.7% | $49.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $59.1M +10.9% | $53.3M +5.1% | $50.8M +0.0% | $50.8M +3.7% | $49.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Immix Biopharma, Inc.
NASDAQ:IMMX
$459.70M
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
$266.95M
MacroGenics, Inc.
NASDAQ:MGNX
$251.71M
Whitehawk Therapeutics Inc
NASDAQ:WHWK
$205.72M
Coya Therapeutics, Inc.
NASDAQ:COYA
$86.31M
Pliant Therapeutics, Inc.
NASDAQ:PLRX
$69.97M
eXoZymes, Inc.
NASDAQ:EXOZ
$60.20M
OKYO Pharma Limited
NASDAQ:OKYO
$58.32M
Estrella Immunopharma, Inc.
ESLA
$45.62M
Anebulo Pharmaceuticals, Inc.
ANEB
$19.37M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does TLSA generate?
Tiziana Life Sciences Ltd (TLSA) reported $0.00 of revenue in fiscal 2025.
Is TLSA profitable?
Tiziana Life Sciences Ltd (TLSA) reported -$18,431,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.